Entheon acquires a genetic screening company to identify genetic markers that affect reactions to hallucinogenic drugs.
Articles
Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units
Mydecine announces a bought-deal financing with units priced at CAD$0.50.
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
NEW YORK, Jan. 14, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer.
Mydecine Innovations Group Upsizes Previously Announced Bought Deal
Mydecine's bought-deal financing is upsized by 50% to CAD $15 million.
UFC looks into Johns Hopkins study on psychedelic drugs as potential therapy for fighters
The UFC is looking to get involved with research into psychedelic drugs as a therapy for fighters' brain health.
Top Texas Lawmakers Say Medical Marijuana Expansion Is On The Table For 2021
As Texas lawmakers returned to work for a new session this week, leaders of both chambers of the state’s legislature said they expect to see action on marijuana bills this year, particularly when it comes to expanding the state’s limited medical cannabis program.
Mexico Publishes Medical Cannabis Regulations
This Tuesday, Mexico quietly passed and published rules that would regulate medical cannabis, setting up Mexico for a nation-wide cannabis industry, and taking another step towards overall cannabis reform in a nation that has been under the spotlight for a long time when it comes to cannabis regulation.
Novamind Expands Psychedelic Medicine Access in Utah
Novamind Inc announces the expansion and optimization of its Cedar Psychiatry clinic in Utah.
This is Why the Psilocybin Story is Quickly Gaining Momentum
Clinical studies continue to support the use of psilocybin for mental health. For example, a study from JAMA Psychiatry found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR.
ATAI or MindMed: Which Is The Better Opportunity?
ATAI Life Sciences and MindMed Inc have the deepest psychedelics operations in this sector. Which is the better opportunity?
Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
MindCure signs LOI to make a strategic investment in ATMA, a psychedelics-assisted therapy center in Calgary, Alberta.
MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers
MindMed commences LSD microdosing study on various health-and-wellness benefits.
Michigan Prosecutor Won’t Pursue Most Marijuana Or Psychedelics Cases, ‘Regardless Of The Amount’
A county prosecutor in Michigan announced on Tuesday that his office will not be pursuing charges over possessing marijuana or entheogenic substances like psilocybin and ayahuasca — “regardless of the amount at issue.”
Washtenaw County Prosecutor: No more charges in cannabis, psychedelic plant cases
ANN ARBOR – Washtenaw County Prosecutor Eli Savit announced Tuesday that his office will no longer bring charges in cases related to marijuana or entheogenic plant use, possession or small-scale distribution.
Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition
Cybin announces the API synthesis of multiple tryptamine derivatives.